Search Results 1051-1060 of 18659 for Relapse
The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
... relapse and reduction in corticosteroid requirement. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...
This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory ...
... relapsed NSCLC. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma. Rochester, Minn ...
Patients at high risk of relapse are eligible for InPACT-pelvis, where they ... Also, to improve disease control by decreasing the number of spinal relapses ...
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
However, the response to PARP inhibitors is much more limited when ovarian cancer has relapsed during PARP inhibitor treatment or when the cancer lacks HR ...
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia ...
... relapsed/refractory multiple myeloma and are scheduled to receive chimeric antigen receptor (CAR)-T cell therapy (CAR-T cell therapy). The YMCA and Mayo ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.